According to Securities Star News, on December 13, 2024, Baike Biotechnology (688276) announced that China Securities Construction Investment and Harvest Fund will investigate our company on December 12, 2024.

The details are as follows:

Q: The answer was repeated in previous institutional surveys, and it was not introduced in the disclosure documents of this event.

Answer: The question was repeated in the previous institutional survey, and it was not introduced in the disclosure document of this event.

1. What is the company's overall operating situation in the first three quarters?

In the first three quarters of 2024, the company achieved operating income of 1026.0123 million yuan, a decrease of 217.181 million yuan, or 17.47%, from 1243.1933 million yuan in the same period of the previous year; net profit attributable to shareholders of listed companies was 244.3698 million yuan, compared with 331.0932 million yuan in the same period of last year, a decrease of 86.7234 million yuan, a decrease of 26.19%; The net profit attributable to shareholders of listed companies after deducting non-recurring gains and losses was 244.8697 million yuan, compared with 325.8086 million yuan in the same period of last year, a decrease of 80.9389 million yuan or 24.84%. Among them, the sales revenue of chickenpox vaccine accounted for slightly more than 60% of the operating income, and the revenue increased slightly; The sales revenue of herpes zoster vaccine accounted for slightly more than 20% of operating income; The rest were nasal spray influenza vaccines, with a slight increase in revenue compared to last year.

2. What is the reason for the decline in sales of the company's herpes zoster vaccine compared with last year?

In 2024, due to the influence of the external environment, the willingness of adults to be vaccinated will decline; Due to the impact of reduced inventory, herpes zoster vaccine shipments decreased compared with the same period last year, and revenue decreased. In response to the above unfavorable factors, the company continued to promote the digital marketing business of live attenuated herpes zoster vaccine by increasing the number of promoters and broadening publicity channels, and strived to improve the awareness and willingness of end customers to receive herpes zoster disease and vaccine.

3. Are there any obvious features in the current user images of herpes zoster vaccination

At present, among the herpes zoster vaccinations, 40-60 years old are vaccinated, and women account for a large proportion of them.

4. Will the company consider adjusting the price of influenza vaccine in the future?

At present, the price of the company's influenza vaccine has not been adjusted.

5. What is the overseas situation of the company's products?

Since the company's chickenpox vaccine has been exported to India, Indonesia, Pakistan, Ghana, Afghanistan and other countries. Among them, chickenpox vaccine was newly exported to Afghanistan; Herpes zoster vaccine was exported to Colombia for the first time. In addition, the company continues to promote the registration of products in Russia, the Middle East and other regions, and with the orderly development of international registration and market development, it will lay a solid foundation for further increasing the sales share and market share of the international market in the future.

6. What are the products under development, and what stage are they currently in?

The company has actively promoted the progress of various projects under research and further consolidated the foundation, and up to now, a number of pipeline products under research have made key progress

The marketing authorization application for live attenuated nasal spray influenza vaccine (liquid preparation) has been accepted, and the on-site inspection of the production site and clinical trial site has been completed;

The fully human anti-tetanus toxin monoclonal antibody initiated a phase I/II clinical study and is currently undergoing a phase I clinical trial;

The fully human anti-rabies virus monoclonal antibody has completed the phase I clinical trial and will enter the phase II clinical trial in July 2024.

Lyophilized human rabies vaccine (human diploid cells) is being prepared for clinical trials;

Herpes simplex virus-2 vaccine and Haemophilus influenzae type b conjugate vaccine have submitted IND applications and been accepted;

Recombinant herpes zoster vaccine and adjuvanted influenza vaccine have been submitted for Pre-IND.

In addition, the company will continue to promote the clinical research of the adsorbed acellular diphtheria-pertussis (three-component) combination vaccine project; Promote the preclinical research of a number of R&D projects such as respiratory syncytial virus vaccine, recombinant human anti-respiratory syncytial virus monoclonal antibody injection, and Alzheimer's disease therapeutic vaccine, and continue to enhance core competitiveness.

Baike Biotech (688276) main business: a high-tech biopharmaceutical enterprise specializing in the research and development, production and sales of human vaccines.

According to the third quarter report of Baike Biotechnology in 2024, the company's main revenue was 1.026 billion yuan, a year-on-year decrease of 17.47%; the net profit attributable to the parent company was 244 million yuan, a year-on-year decrease of 26.19%; deducted non-net profit of 245 million yuan, a year-on-year decrease of 24.84%; In the third quarter of 2024, the company's single-quarter main revenue was 408 million yuan, a year-on-year decrease of 40.37%; the net profit attributable to the parent company in a single quarter was 107 million yuan, a year-on-year decrease of 51.41%; deducted non-net profit of 110 million yuan in a single quarter, a year-on-year decrease of 50.06%; The debt ratio was 20.96%, the investment income was 172,100 yuan, the financial expenses were 3.242 million yuan, and the gross profit margin was 85.5%.

A total of 2 institutions have rated the stock in the last 90 days, and 2 have given a buy rating.

Here's the detailed earnings forecast information: